Combined inhibition of topoisomerases I and II - is this a worthwhile/feasible strategy?
1997

Combining Topoisomerase Inhibitors: Is It Worth It?

Sample size: 27 Editorial Evidence: low

Author Information

Author(s): PA Vasey, SB Kaye

Primary Institution: University of Glasgow

Hypothesis

Can combining topoisomerase I and II inhibitors lead to better cancer treatment outcomes?

Conclusion

The combination of topoisomerase I and II inhibitors does not significantly improve anti-tumor efficacy and may increase toxicity.

Supporting Evidence

  • Preclinical studies showed conflicting results when combining topoisomerase I and II inhibitors.
  • Sequential administration of these inhibitors generally resulted in additive/synergistic cytotoxicity.
  • Clinical trials have shown that neutropenia is a major dose-limiting toxicity in combined treatments.

Takeaway

Doctors are trying to use two types of cancer-fighting medicines together, but it doesn't seem to work better than using just one, and it can make people feel worse.

Methodology

The editorial discusses findings from various clinical trials and preclinical studies on the effects of combining topoisomerase inhibitors.

Limitations

Clinical trials have not confirmed the expected benefits of combining these inhibitors, and many patients experienced severe side effects.

Participant Demographics

Patients with untreated non-small cell lung cancer (NSCLC) and refractory tumors.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication